• In May 2022, Xiromed LLC expanded its hormone therapy offerings by launching a new formulation of progesterone injection USP, 500 mg/10 mL in a multiple-dose vial. This followed the company’s earlier product, progesterone injection USP, 50 mg/mL, and marked a strategic move to diversify its product line. The introduction of this higher-dose format strengthened Xiromed’s position in the progesterone market and enhanced its appeal to a broader range of healthcare providers and consumers.

• In November 2021, Fuji Pharma Co., Ltd. introduced the F-meno capsule, a 100 mg organic progestogen medication developed to prevent endometrial hyperplasia. This product launch marked a key addition to the company’s hormonal therapy portfolio in Japan. By addressing a specific gynecological need, the F-meno capsule enabled Fuji Pharma to strengthen its market presence and attract a wider patient base.

• In May 2023, the U.S. FDA approved Veozah, a treatment developed to relieve symptoms such as flushing and excessive sweating commonly experienced by women with low estrogen levels. This approval marked a significant advancement in managing menopause-related discomfort, offering patients a targeted and clinically validated therapeutic option.

In this report, the Progesterone Market has been segmented by Product Type, Mode of Delivery, Application, and Geography.

Progesterone Market, Segmentation by Product Type

The Progesterone Market has been segmented by Product Type into Natural Progesterone and Synthetic Progesterone.

Natural Progesterone
Natural progesterone is derived from plant sources and is used widely in hormone replacement therapy and the treatment of menstrual disorders and menopause symptoms. It is preferred for its bioidentical composition and minimal side effects. This segment holds approximately 55% of the market share.

Synthetic Progesterone
Synthetic progesterone, also known as progestin, is manufactured through chemical synthesis and is commonly used in oral contraceptives, fertility treatments, and endometrial disorders. It is valued for its longer shelf life and stronger efficacy in targeted therapies. This segment accounts for about 45% of the market share.

Progesterone Market, Segmentation by Mode of Delivery

The Progesterone Market has been segmented by Mode of Delivery into Injectable, Suspended Form, Oral, and Others.

Injectable
Injectable progesterone is widely used in fertility treatments and assisted reproductive therapies due to its fast absorption and high efficacy. It is commonly administered in clinical settings. This mode of delivery holds about 40% of the market share.

Suspended Form
Suspended formulations are designed for topical or vaginal use, offering localized delivery with reduced systemic side effects. They are preferred for menopause management and endometrial protection. This segment accounts for approximately 25% of the market share.

Oral
Oral progesterone is commonly used for hormonal imbalances, menstrual irregularities, and birth control. It provides ease of use and high patient compliance, making it suitable for daily treatment regimens. This segment represents around 30% of the market share.

Others
This category includes transdermal patches and implantable devices designed for controlled release and long-term therapy. Though less common, these options are gaining traction for their convenience. The segment contributes about 5% of the market share.

Progesterone Market, Segmentation by Application

The Progesterone Market has been segmented by Application into Menopause, Dysfunctional Uterine Bleeding, Endometrial Cancer, Contraception, Hyperplastic Precursor Lesions, and Others.

Menopause
Progesterone is widely used in hormone replacement therapy to relieve menopausal symptoms such as hot flashes, night sweats, and osteoporosis prevention. It is often combined with estrogen for balanced therapy. This segment holds approximately 30% of the market share.

Dysfunctional Uterine Bleeding
In cases of abnormal or irregular menstrual bleeding, progesterone helps restore endometrial balance and regulate the menstrual cycle. It is widely prescribed for both acute and chronic conditions. This segment accounts for about 20% of the market share.

Endometrial Cancer
Progesterone therapy is used to treat endometrial hyperplasia and early-stage endometrial carcinoma, especially in patients desiring fertility preservation. It works by suppressing endometrial cell growth. This segment represents around 15% of the market share.

Contraception
As a key ingredient in oral contraceptives and injectable birth control methods, progesterone helps prevent ovulation and maintain cervical mucus consistency. This segment contributes approximately 18% of the market share.

Hyperplastic Precursor Lesions
Progesterone is used to manage endometrial hyperplasia without atypia and other precancerous conditions by promoting endometrial shedding and reducing abnormal tissue growth. This segment holds about 10% of the market share.

Others
This category includes applications in treating premenstrual syndrome, infertility, and luteal phase support in IVF cycles. Although niche, these uses are steadily growing. This segment contributes around 7% of the market share.

Progesterone Market, Segmentation by Geography

In this report, the Progesterone Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Progesterone Market Share (%), by Geographical Region

North America
North America leads the progesterone market due to the widespread use of hormone replacement therapies, a high prevalence of reproductive health disorders, and advanced healthcare systems in countries like the United States and Canada. The region accounts for approximately 40% of the market share.

Europe
Europe holds a significant share supported by the increasing adoption of oral contraceptives and strong demand for menopausal hormone therapy. Countries such as Germany, France, and the United Kingdom are major contributors. This region holds about 28% of the market share.

Asia Pacific
Asia Pacific is experiencing rapid growth due to rising awareness of women’s health, growing access to gynecological care, and increasing demand for fertility treatments in countries like China, India, and Japan. The region contributes approximately 22% of the market share.

Middle East and Africa
The Middle East and Africa region is gradually expanding due to growing investments in healthcare infrastructure and improving access to reproductive health services, particularly in urban areas. It accounts for about 6% of the market share.

Latin America
Latin America is witnessing steady growth driven by increased awareness of contraceptive use and expanding public health initiatives related to women’s health in countries like Brazil and Mexico. This region holds around 4% of the market share.

This report provides an in depth analysis of various factors that impact the dynamics of Progesterone Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis